Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Dummer

Showing results (301-310 of 328) with videos related to

Pageof 33
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|July 17, 2021
Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trialR A Cowan, J J Scarisbrick, P L Zinzani, et al.
ESMO Open|May 26, 2026
Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02CM Tetzlaff, J M Taube, G V Long, et al.
Journal of Cancer Research and Clinical Oncology|June 16, 2017
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumabC Brüggemann, M C Kirchberger, S M Goldinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patientsU Keilholz, C Conradt, S S Legha, et al.
The British Journal of Dermatology|September 24, 2019
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT studyR Dummer, A Guminksi, R Gutzmer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyP B Chapman, C Robert, J Larkin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2017
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialN Basset-Séguin, A Hauschild, R Kunstfeld, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 29, 2017
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT studyJ T Lear, M R Migden, K D Lewis, et al.
Oncogene|March 3, 2015
Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapyE Lau, J Sedy, C Sander, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 20, 2020
Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre studyM-C Brüggen, J Valencak, R Stranzenbach, et al.
Pageof 33

Showing results (301-310 of 328) with videos related to

Sort By:
Pageof 33
Journal of the European Academy of Dermatology and Venereology : JEADV|July 17, 2021
Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trialR A Cowan, J J Scarisbrick, P L Zinzani, et al.
ESMO Open|May 26, 2026
Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02CM Tetzlaff, J M Taube, G V Long, et al.
Journal of Cancer Research and Clinical Oncology|June 16, 2017
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumabC Brüggemann, M C Kirchberger, S M Goldinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patientsU Keilholz, C Conradt, S S Legha, et al.
The British Journal of Dermatology|September 24, 2019
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT studyR Dummer, A Guminksi, R Gutzmer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 studyP B Chapman, C Robert, J Larkin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2017
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trialN Basset-Séguin, A Hauschild, R Kunstfeld, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 29, 2017
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT studyJ T Lear, M R Migden, K D Lewis, et al.
Oncogene|March 3, 2015
Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapyE Lau, J Sedy, C Sander, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 20, 2020
Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre studyM-C Brüggen, J Valencak, R Stranzenbach, et al.
Pageof 33